Bactiguard (BACTI) Q4 2024 earnings summary

Executive summary

• License-focused strategy resulted in increased revenues and a return to EBITDA profitability for 2024, with total revenue up 17.3% year-over-year to SEK 261.9 million and three consecutive quarters of positive financial development.

• Strategic shift included discontinuing the BIP portfolio and transitioning Foley catheter markets to BD, realizing significant cost savings and reallocating resources to licensing and wound management.

• Strengthened the organization with key hires in R&D, regulatory, clinical, and business intelligence, supporting future growth and innovation.

• Technology demonstrated strong clinical efficacy, with recent studies showing approximately 70% infection risk reduction.

Financial highlights

• Q4 2024 total revenues reached SEK 68.3 million, up 11.3% year-over-year; full year revenues were SEK 261.9 million, an increase of SEK 38.7 million, or close to 13% growth adjusted for currency.

• Q4 EBITDA was SEK 8.4 million (margin 12.4%), up almost SEK 13 million year-over-year; full year EBITDA was SEK 18.0 million (margin 6.9%), a SEK 94 million improvement.

• Net loss narrowed to SEK 29.8 million from SEK 138.4 million in 2023.

• Cash flow from operating activities for 2024 was SEK 25.0 million, up from SEK -52.3 million in 2023; year-end cash and equivalents stood at SEK 116.7 million.

• Full year OpEx decreased by SEK 27.3 million (12%), with annual cost savings exceeding SEK 25 million.

Outlook and guidance

• Financial targets for 2028 are under review due to the Zimmer Biomet agreement termination; updated targets to be announced by end of Q1 2025.

• Focus remains on advancing license partnerships, expanding wound management in Asia, and maintaining cost control to support EBITDA profitability.

• Zimmer Biomet trauma agreement revenues will continue, but revenues from the discontinued orthopedics agreement will not recur in 2025.

• No dividend proposed for 2024.